Tuning the Tumor Myeloid Microenvironment to Fight Cancer
- 1Pionyr Immunotherapeutics Inc., United States
- 2Immunology Program, Sloan Kettering Insitute, Memorial Sloan Kettering Cancer Center, United States
- 3Departments of Pathology and Laboratory Medicine, University of California, San Francisco, United States
The tumor microenvironment (TME) of diverse cancer types is often characterized by high levels of infiltrating myeloid cells including monocytes, macrophages, dendritic cells, and granulocytes. These cells perform a variety of functions in the TME, varying from of immune suppressive to immune stimulatory roles. In this review, we summarize the different myeloid cell populations in the TME and the intratumoral myeloid targeting approaches that are being clinically investigated, and discuss strategies that identify new myeloid subpopulations within the TME. The TME therapies include agents that modulate the functional activities of myeloid populations, that impact recruitment and survival of myeloid subpopulations, and that functionally reprogram or activate myeloid populations. We discuss the benefits, limitations and potential side effects of these therapeutic approaches.
Keywords: tumor micoenvironment, Macropahge, Tumor associated macrophage (TAM), Immune checkpoint blockade (ICB), dendritic cell (DC), Myeloid Cells, Myeloid Tuning, Monocytes
Received: 01 May 2019;
Accepted: 27 Jun 2019.
Edited by:Jeffrey W. Pollard, MRC Centre for Reproductive Health (MRC), University of Edinburgh, United Kingdom
Reviewed by:Jo A. Van Ginderachter, Vrije University Brussel, Belgium
Luca Cassetta, University of Edinburgh, United Kingdom
Copyright: © 2019 Jahchan, Mujal, Pollack, Binnewies, Sriram, Reyno and Krummel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Nadine S. Jahchan, Pionyr Immunotherapeutics Inc., South San Francisco, United States, firstname.lastname@example.org
Dr. Matthew F. Krummel, Departments of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, United States, email@example.com